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Engineering Recombinant Antibodies for the Detection of Axonal FMRP Spliceforms                                          
Steven G. Doll                                                                                                                                                   
Michael R. Akins, Ph.D. 
Epigenetic silencing of the fragile X mental retardation protein (FMRP) is 
understood to be the primary causative agent of fragile X syndrome (FXS), a well 
characterized cause of intellectual disability and autism.  This raises the question as to 
the functions of FMRP in the normal brain, and how loss of the protein results in 
dysregulated plasticity.  FMRP is an mRNA binding protein that negatively regulates 
translation of its mRNA targets.  Attempts to identify mRNA sequence motifs and mRNA 
secondary structures that FMRP might recognize has only managed to account for a 
fraction of the total mRNAs the protein may associate with.  Furthermore, mRNAs are 
large, and would likely require the effects of multiple proteins to stall translation.  Thus, it 
may be the case that FMRP operates alongside other proteins in a co-regulatory 
complex.     
In order to probe the functions of FMRP, it is necessary to have the proper tools 
and a working model.  To the first point, a method for the production of recombinant 
antibodies against FMRP has been devised that makes use of simple molecular 
techniques including PCR and restriction cloning as opposed to maintenance of anti-
FMRP producing hybridomas.  To the second point, we have tested a mouse model by 
which the olfactory bulb may be used to detect specific isoforms of FMRP.  Localization 
of specific isoforms to a discrete region of the neuron in vivo would suggest a particular 
function of those isoforms.  If FMRP does not operate alone, this would suggest that 
specific isoforms are required to participate in specific protein complexes.  Loss of 
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FMRP expression would disrupt formation of these complexes and their effects upon 
translational regulation. 
We were able to successfully produce a method for the cloning of recombinant 
anti-FMRP antibody.  However, the mouse model through which we would detect 
specific FMRP isoforms proved incapable of providing interpretable results.  
Nonetheless, we wish to test our method of recombinant antibody production in an effort 
to provide a useful technique for the community on the whole and eliminate the need to 























Chapter I: Overture 
Etiology of fragile X syndrome  
Fragile X syndrome (FXS) was initially characterized by an apparently weakened 
association at the distal q arm of the X chromosome (Lubs, 1969).  However, it would 
later become clear that it was not the fracture itself that was responsible for FXS, rather 
FXS associated with chromosome instability (Vekemans et al., 1983).  Indeed, the core 
of FXS features the epigenetic silencing of the FMR1 gene, which encodes the fragile X 
mental retardation protein (FMRP) (Penagarikano et al., 2007).  Expansion of a CGG 
repeat within the 5’ untranslated region (UTR) of exon 1 to >200 repeats promotes 
methylation and subsequent transcriptional inactivation FMR1 (Penagarikano et al, 
2007; Jin et al., 2000).  Loss of FMR1 expression, and correspondingly, a loss of 
FMRP, manifests as FXS.  FMRP functions as a translational regulator within the brain, 
associating with specific mRNAs and stalling ribosome movement as a member of 
messenger ribonuclearprotein (mRNP) particles (Darnell et al., 2011).  While the 
downstream effect of FMRP function is well understood, the exact mechanism by which 
the protein exerts its effects upon translational regulation remains to be elucidated.  In 
the case of FXS, FMRP is not being expressed, and thus maintenance of translation on 
a spatio-temporal scale is abrogated.  It is therefore important to determine how exactly 
FMRP identifies its target mRNAs and halts their translation as such a process is absent 
in the FXS brain.  
FMRP functions in translational regulation 
FMRP possesses two K-homology (KH) domains, KH1 and KH2, which are 
believed to participate in mRNA binding (Ashley et al., 1993; Valverde et al., 2007).  The 
protein also contains an RGG box that interacts with target mRNAs (Ramos et al., 
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2003).  Interestingly, the KH domains and RGG box possess significant disorder, with 
not only RNA binding (Bardoni et al., 2002), but also protein/protein interaction. There 
exist two competing hypotheses regarding the nature of FMRP translational inhibition.  
The first suggests that FMRP is capable of recognizing secondary structures within its 
target mRNAs by virtue of its KH domains (recognizing pseudoknot structures) and 
RGG box (recognizing G-quadruplex structures) (Ashley et al., 1993).  The second 
suggests that FMRP recognizes specific short mRNA sequences, and without these 
sequences binding specificity is lost (Ascano et al., 2012).  However, neither of these 
hypotheses can account for the ability of FMRP to associate with a vast number of 
mRNA targets.  Darnell et al. (2011) determined that FMRP associated with over 800 
mRNAs; that FMRP could recognize that many targets given either the mRNA 
secondary structure or sequence requires additional hypotheses.  Recently, Chen et al. 
(2014) resolved the crystal structure of the FMRP-ribosome association, verifying that 
the protein does bind the ribosome.  However, the authors proposed a model by which 
FMRP would become lodged within the ribosome after binding G-quadruplexes of its 
mRNA targets.  Such a conclusion was insufficient given that not all FMRP targets 
identified by Darnell et al. (2011) could form G-quadruplex secondary structures 
(Darnell et al., 2011; Chen et al., 2014). 
The function of FMRP as a negative regulator of translation has been extensively 
studied at the post-synapse (Doyle and Kiebler, 2011; Darnell and Klann, 2013).  FMRP 
expression is necessary for translational initiation within post-synaptic mRNP particles 
(Weiler et al, 2004), which while perhaps contrary to the FMRP paradigm of negative 
regulation, indicates that the protein plays a key role in mRNP particles.  The overall 
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model of FMRP function at the post-synapse has the protein incorporated into mRNP 
particles in the soma and transported along a microtubule highway to a dendritic spine 
(Doyle and Kiebler, 2011).  Once the mRNP particle has been localized to the post-
synapse, FMRP proceeds to interfere with active translation through binding target 
mRNAs and occluding the active site of the 80S ribosome (Darnell and Klann, 2013).  
We wish to explore the dynamics of FMRP association with mRNP particles at the pre-
synapse, and the effects the protein has upon translation within axons.  In this way, we 
might provide a more complete picture of FMRP function by determining its effect upon 
translation in pre-synaptic compartments.   
A pre-synaptic role for FMRP 
In the axon, FMRP has been found to associate in structures termed fragile X 
granules (FXGs) (Christie et al., 2009).  The FXG necessarily includes the FMRP 
homologue FXR2P and may also include a second homologue FXR1P (Christie et al., 
2009).  FMRP has been shown to physically interact with both FXR1P and FXR2P in 
vitro (Cerman et al., 1999; Schench et al., 2001). The FXG may serve as a means of 
local translational regulation within the axon. However, this would require the presence 
of ribosomes in addition to translational regulators.  Recent data from our lab suggests 
that these granules do indeed possess ribosomes (Akins et al. 2016; manuscript in 
review).  Thus the FXG may serve a similar function in axons as in dendrites, where the 
protein associates in distinct granules that contact F-actin bundles (Antar at al., 2005).   
It is interesting, then, to consider the relationship between FXR2P and the FXG.  
From our data we have found that every instance of an FXG within the axon includes 
FXR2P.  FXR2P, by virtue of its homologies with FMRP, may serve as a primary 
4 
 
translational regulator within the FXG.  FXR1P and FMRP may also be present within 
the FXG; however they are not necessary components.  Addition of mRNA binding 
proteins beyond FXR2P likely increases the stringency of translation.  
FMRP spliceforms 
Similar to many other proteins, FMRP is subject to alternate splicing at the 
mRNA level.  As of the publication of this work, there exist 12 characterized FMRP 
spliceforms.  Of particular interest are those spliceforms with a shortened exon 15, 
which contains the RGG box (Brackett et al., 2013).  Specific arginine residues within 
the RGG box are sites of methylation (Dolzhanskaya et al., 2006a; Brackett et al., 
2013).  Methylation at these residues has been demonstrated to be necessary for 
FMRP interaction with FXR1P and certain target mRNAs (Dolzhanskaya et al., 2006b, 
Blackwell et al., 2010).  Further, alternate splicing may produce spliceforms with a 
frameshift mutation that results in a loss of the RGG box (Brackett et al., 2005).  Thus, it 
is a question of spliceform localization throughout the neuron, with different spliceforms 
serving different functions on a spatiotemporal basis.  Certain spliceforms may be 
localized to certain mRNP particles on the basis of the constituent proteins of that 
particle and the mRNAs present within that particle.  Preliminary data from our lab 
suggests that FMRP spliceforms do not display distinct sub-cellular localization; 
however, over-expression of certain spliceforms has an effect upon the level of 
complexity of the axonal arbor (Zimmer et al., manuscript in preparation).  It is of note 
that this work was conducted in cortical neurons and may not be reflective of events 
within the complete brain. 
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That methylation within the RGG box would affect not only mRNA interactions 
but also protein interactions are indicative that FMRP does not function as a ‘lone 
ranger’ of translational regulation.  Indeed, FMRP interacts with other proteins when a 
member of mRNP particles.  The uncertainty remains in exactly which proteins FMRP 
binds and the nature of complexes that are formed.  We explore FMRP interacting 
proteins in the proceeding section and discuss the mechanism by which these 
associations serve to regulate translation.    
FMRP interacting proteins 
It is proposed here that FMRP is capable of recognizing target mRNAs not 
necessarily by virtue of its own structure but through association with other mRNA 
binding proteins.  Through these associations FMRP participates in what I refer to as 
the ‘FMRP co-regulatory complex’.  The formation of such a complex enhances the 
ability of FMRP to bind the large number of mRNAs identified by Darnell et al. (2011).  
There is evidence for a co-regulator complex; that is, other proteins associate with 
FMRP in the mRNP particles and modulate its mRNA binding function.  FMRP 
physically interacts with cytoplasmic FMRP interacting protein (CYFIP) (Napoli et al., 
2008; Bardoni et al., 2002) and eukaryotic translation initiation factor 4E (eIF4E). 
Furthermore, these three proteins eluted with monoribosomes (Napoli et al., 2008).  
FMRP forms a complex with elF4E and CYFIP1/2 when binding target mRNAs (De 
Rubeis and Bagni, 2011), and such a complex sequesters CYFIP1/2 (Abekhoukh and 
Bardoni, 2014).  With a reduced pool of CYFIP1/2, formation of the WAVE complex 
(which includes WAVE1, a player in actin polymerization) may be impaired, allowing for 
increased activation of WAVE1 (Takenawa and Suetsugu, 2007).  The WAVE1 protein 
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regulates actin polymerization and so an FMRP co-regulator complex may both 
proximally regulate translation by virtue of the mRNP particle, but ultimately affect 
cytoskeletal dynamics and the morphology of the axon.  This would link FMRP 
translational control with WAVE1 signaling.  In addition to eIF4E, the FMRP/CYFIP1/2 
complex has been shown to include FXR1P and FXR2P (Schenk et al., 2001).  
Interaction with FXR1/2P and CYFIP1/2 requires exon 7 (Schenck et al., 2001; Bardoni 
and Mandel, 2002), which is included in all spliceoforms of FMRP (Brackett et al., 
2013).  NUFIP2 also requires exon 7 for interaction with FMRP, however the exact 
function of this protein remains to be determined (Bardoni et al., 2003). 
FMRP also physically interacts with Caprin1 in WT mouse brain.  FMRP and 
Caprin1 were found to fractionate with polyribosomes in a sucrose gradient.  
Interestingly, several mRNA targets of FMRP were found in these fractions (El Fatimy et 
al., 2012).  Caprin1 has been shown to function as an mRNA binding protein in a similar 
manner as FMRP (El Fatimy et al., 2012; Solomon et al., 2007).  Figure 1.1a illustrates 
the FMRP co-regulator complex hypothesis with FMRP serving as the central docking 
protein.  Figure 1.1b illustrates a co-regulator complex in which FMRP is an auxiliary 
component of the complex.  In both models, loss of FMRP affects the formation of the 
complex and/or the diversity of mRNAs that may be recognized and targeted. 
Rather than a distinct co-regulator complex, it may be the case that FMRP is 
capable of interacting with such a diverse array of mRNAs by virtue of simply being 
present within the mRNP particle.  This would hinge upon the physical size of the 
particle, the number of mRNAs present, and the quantity of FMRP within the particle.  In 
each case that FMRP is transported to an mRNP particle, be it axonal or dendritic, it 
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may be able to collide with each and every mRNA provided the kinetics mediated by the 
size of particle.  Those that ‘stick’ to FMRP would make a high number of favorable 
contacts with the protein.  The structural data provided by Chen et al. (2014) would then 
prove sufficient to explain this role of FMRP.  It is not FMRP that is responsible for 
mRNA binding, but rather the environment of the mRNP particle.  FMRP does not 
recognize RNA secondary structures, but may be able to maintain a stronger 
association with mRNAs possessing secondary structures once contact has been 
made.  This proposed function of the particle itself eliminates the need for an FMRP co-
regulator complex.  FMRP would not require an association with other RNA binding 
proteins as such a complex would not have any particular targets.  Rather, FMRP would 
transiently interact with other RNA binding proteins that may or may not result in a 
strong association between FMRP and an mRNA.  In other words, other RNA binding 
proteins within the mRNP particle would enhance the kinetics by which FMRP binds 
mRNAs.  A loss of FMRP would not disrupt a protein complex, but would reduce the 
overall ability of an mRNP particle to negatively regulate translation.  This ‘stochastic 
model’ of FMRP function is illustrated in Figure 1.1c.   
Production of recombinant antibodies for detection of FXG components 
Elucidation of the translational machinery that resides within the FXG is 
paramount to an understanding of the function of these RNP particles in modulating the 
axonal protein synthesis.  As previously hypothesized, the components of the FXG may 
have the capacity to function as FMRP co-regulators, and such would appear the case 
for the FMRP homologues FXR1P and FXR2P (Ceman et al., 1999; Schenck et al., 
2001).   Prior to an investigation of the interactions of FMRP with its homologues within 
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the FXG, it is necessary to have a reliable means to detect the components of FXGs at 
the pre-synapse.  FXGs only require FXR2P; FMRP and FXR1P are auxiliary.  Those 
granules that possess FMRP in addition to FXR2P would regulate a different set of 
mRNAs than those granules possessing only FXR2P.  In turn, those granules with 
FMRP would have different co-regulatory complexes that those with only FXR2P.  In 
order to identify components of FXGs in axons, specifically FMRP-containing FXGs, we 
adopted a cloning technique from Crosnier et al. (2010) towards the production of 
recombinant antibodies against FMRP, FXR2P and rRNA.  Production of recombinant 
antibodies made use of isotype switching (Crosnier et al., 2010), which naturally occurs 
during differentiation beta-lymphocytes (Stavnezer et al., 2008). Prior to antigen 
exposure, beta-lymphocytes have already experienced chromosomal rearrangements at 
the loci corresponding to light and heavy chains.  Within the light chain gene, a variable 
region is spliced next to a downstream joining region.  The joining region is positioned 
upstream from a constant region.  There are two types of light chain constant regions, 
lamba and kappa.  Here we are particularly concerned with light chains possessing the 
kappa constant region.   
Within the heavy chain gene, a variable region is spliced next to a downstream 
diversifying region, which is in turn spliced next to a downstream joining region.  The 
joining region is positioned upstream from the constant regions.  At this point in beta-
lymphocyte development, the constant region consists of multiple chains (gamma 
chains, alpha chains, delta chains, epsilon chains, and mu chains).  It is the composition 
of the constant region of the heavy chain that determines the isotype of the 
immunoglobulin.  Upon exposure to an antigen, the beta-lymphocyte experiences 
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further differentiation by which a single constant region is selected and positioned 
downstream of the diversifying region, while the other constant regions are spliced out 
of the sequence (Kirkham et al., 1994; Manis et al. (2002).  Thus, a heavy chain 
sequence including only gamma chains would produce and immunoglobulin gamma 
(IgG) after association with a complete light chain.  According to Crosnier et al., (2010),  
the variable regions from the light and heavy chain of anti-bodies raised against FMRP, 
FXR2P, and ribosomal RNA could be cloned and inserted in front of kappa-light chain 
constant region and IgG1 heavy chain constant region, respectively (see Figure 1.2).  
This would allow for isotype switching from the parent immunoglobulin class to an IgG1 
while retaining antigen specificity.  It must be noted that isotype switching is only 
possible amongst immunoglobulin subclasses.  That is, an IgG2a or IgG2b may be 
switched to an IgG1 and retain antigen specificity, while an IgM could not be switched to 
an IgG (IgG1, IgG2a, or IgG2b).  The structural interactions between the heavy chain 
constant region and the and the variable regions during antigen binding prevent class 
switching through this method (Sheriff et al., 1987; Guddat et al., 1993; Vidarsson et al., 



































Figure 1.1a  The FMRP co-regulator hypothesis.  FMRP associates with 
other proteins in complex that modulate the mRNA binding specificity of 
FMRP.  FMRP serves as the central docking protein in this model.  In the 
absence of FMRP, the co-regulator complex does not form, and translational 



























Figure 1.1b  Counter hypothesis in which FMRP does not behave as the 
central docking protein, but rather as an auxiliary member of a protein 
complex.  According to this model, FMRP enhances the specificity of the 
complex for target mRNAs.  In the absence of FMRP, members of the 




























Figure 1.1c Stochastic model of FMRP translational regulation.  By virtue of 
its presence within the mRNP particle, FMRP contacts the mRNAs present 
within that particle.  Certain mRNAs form high-affinity associations with 
FMRP, dependent upon structural interplay between the protein and the 
nucleic acid.  These mRNAs are bound up by FMRP and are not translated.  






























Figure 1.2  Recombination of antibodies of interest required synthesizing the 
variable regions (denoted by arrows) from the light and heavy chains of our 
antibodies of interest through PCR.  After PCR product was obtained for both 
chains, they could be fused to a joining fragment (indicated), and the complete 
contig could be expressed as functional antibody. Vkl:variable region from kappa 
light chain.  Ckl: constant region from kappa light chain. VH: variable region from 





Chapter II: Engineering Recombinant Antibodies Specific to Components of the 
Fragile X Granule (FXG) 
Abstract 
Here we detail our progress towards producing recombinant antibodies against 
FMRP, FXR2P, and rRNA.  The exact sequences for the variable region of the light and 
heavy chain were obtained through SynBuild sequencing and a restriction 
digestion/ligation strategy was designed to insert the variable regions into a pTT3 vector 
derivative.  The pTT3 vector included CMV viral promoters for expression of light and 
heavy chains as well as leader sequences for proper export of antibodies from the host 
cell.  The unique feature of the pTT3 vector was the joining fragment, which we took 
advantage of in our cloning technique.  We hope that the method described here will not 
only serve as a useful tool for antibody production but will also reduce the burden of 
hybridoma maintenance. 
Introduction 
Recombination within the light and heavy immunoglobulin genes occurs in two 
phases during beta-lymphocyte development (Davis et al., 1980).  During the first 
phase, the variable-diversifying-joining (VDJ) sequence is spliced together (in the case 
of the heavy chain; the light chain does not include a diversifying segment).  All heavy 
chain constant (C) sequences remain within the genome during this phase.  Antigen 
contact initiates the second phase of recombination by which a single heavy chain 
constant sequence is selected and positioned downstream of the VDJ sequence (an 
event termed ‘class switch recombination’ or CSR (Li et al., 2004).  The remaining 
heavy chain constant sequences are spliced out of the genome, leaving a complete 
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VDJ-C sequence that may associate with a corresponding light chain after translation 
(Manis et al., 2002).  The light chain VJ region is spliced in front of either a kappa (κ) or 
lamba (λ) constant region during mRNA maturation (Schibler et al., 1978; McBride et al., 
1982). Here we are primarily concerned with light chain possessing the kappa constant 
region. 
The interaction between the variable regions of the light and heavy chains 
defines antigen specificity.  The adaptive immune system is capable of producing 
variable regions capable of recognizing any antigen through the process of somatic 
hypermutation (Manis et al., 2002), Li et al., 2004).  Somatic hypermutation introduces 
polymorphisms within the variable sequence such that no two differentiated beta-
lymphocytes would possess the same sequence.  Two beta-lymphocytes exposed to 
the same antigen would produce antibody against that antigen through use of different 
variable sequences and thus different antigen recognition structures. 
Given such vast sequence diversity amongst variable regions recognizing the 
same antigen, there is no simple path towards the cloning of antibodies.  Rather, the 
preferred method is to immunize an animal with an antigen and select a particular beta-
lymphocyte from a pool (polyclonal source) producing antibody against the antigen and 
maintaining that cell line (monoclonal source of antibody).  This requires fusion of the 
beta-lymphocyte to a myeloma cell to produce a hybridoma.  The hybridoma and its 
descendants produce equivalent forms of the antibody of interest (Nakamura, 1983).   
Crosnier et al. (2010) developed a method for the cloning of monoclonal 
antibodies from cDNA synthesized from extracted hybridoma RNA.  We co-opted the 
technique used by this group in an effort to produce antibodies against FMRP, FXR2P, 
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and ribosomal rRNA.  We hoped to eliminate the need to maintain hybridoma cell lines, 
particularly the anti-FMRP producing hybridoma.  This cell line in particular has proved 
difficult to maintain as it frequently stops producing antibody and must be re-derived 
from the main stock.  Given that this anti-FMRP hybridoma is one of the best sources of 
antibody FMRP, a method that would allow for cloning of this antibody would benefit not 
only our laboratory but other laboratories within the field.   
At the core of the method described by Cronier et al. (2010) was the use of a 
pTT3 vector derivative.  This vector included gene cassettes for the expression of 
murine light and heavy chains against zebrafish NCAM2.  It was our goal to remove the 
variable regions providing specificity to NCAM2 antigen and replace them with variable 
regions corresponding to our antibodies of interest.  In this way, we could simply insert 
variable regions in front of constant regions and produce functional antibody providing 
the introduced variable regions were derived from an antibody of the same isotype 
(same heavy chain constant region composition) as that present in the vector.  The 
heavy chain constant region of the vector was an IgG1.  Any antibody produced using 
this constant region would be expected to behave as an IgG1.  Thus the pTT3 vector 
served as a platform for the production of recombinant antibodies against FMRP, 
FXR2P, and rRNA. 
In our hands, the technique described by Crosnier et al. (2010) proved incapable 
of producing functionally recombined antibodies against FXR2P, FMRP, and rRNA. This 
approach required that the light variable and heavy variable sequences be amplified 
through standard PCR and fused to a joining fragment prior to insertion into the vector.  
Fusion PCR, while executable, did not result in functional antibody after insertion into 
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the parent vector.  This pursuit was abandoned in favor of directly sequencing the 
variable regions and introducing them to the vector through more canonical means. 
Nonetheless, we did manage to obtain the sequence of the kappa light chain variable 
region and heavy chain variable region corresponding to an anti-FMRP antibody 
specific to the N-terminus of the protein.  With these sequences, a new method for the 
cloning of recombinant antibodies, specifically those against the players in the FXG, has 
been developed.  Using the original vector designed by Cronier et al. (2010), we 
designed primers to introduce restriction sites into the kappa light chain variable region 
sequence and heavy chain variable region sequence.  Corresponding restriction sites 
were introduced into the parent vector, allowing for light chain and heavy chain variable 
regions to be ligated to the vector.  We hope to co-opt the method described here for 
the cloning of the light and heavy variable regions of antibodies against FXR2P and 
rRNA. 
Materials and Methods 
Amplification of light and heavy chain variable regions through PCR 
Total RNA was extracted from hybridoma cell lines producing antibodies against 
FMRP (N-terminus), FXR2P, and rRNA through TRIzol-chloroform treatment.  RNA was 
reverse transcribed with M-MuLV reverse transcriptase (NEB) and mixed hexamer 
primers to produce total cDNA for subsequent PCR reactions. 
A series of primer batteries were employed for amplification of the light and 
heavy chains of each antibody as described by Crosnier et al. (2010).  For amplification 
of the light chain, forward primers included degenerate bases to account for 
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randomness within the variable sequence.  The reverse primer was targeted to the light 
chain constant region just downstream of the joining region.   
Primers utilized for amplification of the heavy chain variable region maintained 
the same rationale as employed for light chain primers.  However, due to the high 
number of possible combinations within the heavy chain constant region during gene 
splicing (Li et al., 2004), reverse primers targeted the less variable joining region (there 
exist only four possible joining regions for the heavy chain within the mouse; the number 
and order of constant regions would be orders of magnitude greater).  PCR conditions 
for the amplification of the light variable and heavy variable sequences of anti-FXR2P 
and rRNA were as follows (adapted directly from Crosnier et al. (2010)): 94°C for 5 
minutes, (94°C for 45 seconds, 65°C for 30 seconds, 72°C for 1 minute)x5 cycles, 
(94°C for 45 seconds, 64.5°C-55.5°C touchdown with a 0.5° decrement per cycle, 72°C 
for 1 minute)x19 cycles, and (94°C for 45 seconds, 55°C for 30 seconds, and 72°C for 1 
minute)x10 cycles. 
PCR conditions for the amplification of the light and heavy variable sequences of 
anti-FMRP N-terminus required a higher annealing temperature range during the 
touchdown: 94°C for 5 minutes, (94°C for 45 seconds, 65°C for 30 seconds, 72°C for 1 
minute)x5 cycles, (94°C for 45 seconds, 69°C-60°C touchdown with a 0.5° decrement 
per cycle, 72°C for 1 minute)x19 cycles, and (94°C for 45 seconds, 55°C for 30 
seconds, and 72°C for 1 minute)x10 cycles. 
Amplification of the joining fragment and fusion PCR 
The pTT3 vector derivative described by Crosnier et al. (2010) included a ‘joining 
fragment’ (not to be confused with the joining region of rearranged antibodies) 
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positioned between the VKL and VH.  The joining fragment included the sequence for the 
light chain constant region and a leader sequence for the heavy chain.  Primers from 
Crosnier et al. (2010) were used to amplify the joining fragment.  Equimolar 
concentrations of joining fragment, light chain PCR product, and heavy chain PCR 
product were subjected to fusion PCR, yielding the complete contig depicted in Figure 
1.2.  The fusion PCR product was checked for appropriate length on a 1% agarose gel, 
gel purified, restriction digested, and inserted into empty pTT3 vector. 
HEK293T cell transfection 
HEK293T cells were grown to approximately 80% confluency in a T25 flask prior 
to transfection.  pTT3 constructs containing antibody sequences of interest were 
incubated with FuGENE (Promega) then mixed with cells.  Approximately 7 ug of each 
construct was diluted to a concentration of 200 ng/ul prior to addition HEK293T cells.  
Supernatant was collected 7 days post-transfection, treated with 1% NaN3, flash frozen 
in liquid nitrogen, and stored at -80°C for later use. 
Western blotting 
Supernatant from HEK293T cells transfected with experimental constructs were 
run undiluted on 8% SDS-PAGE resolving gel.  Membranes were incubated with LiCor 
donkey anti-mouse IgG secondary antibody with 680 nm excitation frequency.  A LiCor 
donkey anti-rabbit IgG secondary antibody with 800 nm excitation frequency was used 
to indicate the expression of N-cadherin. 
HEK293T supernatant was used as a source of primary antibody for the 
recognition of FXG components in the mouse olfactory bulb (see Chapter 3 for a more 
detailed description of the preparation and utilization of mouse tissue).  Volumes 
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corresponding to 30 ug of total protein from mouse olfactory bulb were run through an 
8% SDS-PAGE gel.  Membranes were incubated with experimental recombinant 
antibodies, and then incubated with LiCor donkey anti-mouse secondary antibody with 
800 nm excitation frequency. 
SynBuild sequencing of light and heavy chain variable regions 
In addition to the attempts at producing functionally rearranged antibody through 
the method described by Crosnier et al. (2010), total RNA from 2F5 hybridoma 
(corresponding to anti-FMRP N-terminus) was sent to Synbuild 
(http://www.synbuild.com) for sequencing.  Complete sequences corresponding to the 
VKL  and VH were returned and used in the design of a less robust yet more stringent 
method towards the production of recombinant monoclonal antibodies.  Sequence 
analysis made use of geneious bioinformatics software (http://www.geneious.com).  
Results 
Production of recombinant antibodies through fusion PCR 
Amplification of the light and heavy chains of all antibodies of interest produced a 
band of approximately 400 bp in length when run on a 1% agarose gel (Figure 2.1).  
Light and heavy chain PCR product from the anti-ribosomal cDNA was particularly poor 
in quality and could not be used in subsequent fusion PCR (data not shown).  PCR 
product form anti-FMRP and anti-FXR2P was sufficient for downstream application.  We 
were able to synthesize and purify fusion PCR product corresponding to an expected 
size of roughly 2.4 kb (Figure 2.2) using amplified VKL and VH from both anti-FMRP and 
anti-FXR2P cDNA.  Full-length antibodies against both proteins were synthesized in 
HEK293T cells and serum was tested for secondary antibody recognition.  Figure 2.3a 
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demonstrates that secondary antibodies were capable of recognizing the constant 
regions of the synthesized antibodies.  Similar results were obtained for secondary 
antibody binding to unmodified pTT3 vector encoding anti-NCAM2.  To test for proper 
variable region fusion to the joining fragment, and thereby functionally recombinant 
antibodies (see Figure 1.2), HEK293T supernatant from aforementioned transfections 
was used as primary antibody to detect components of FXGs in the mouse olfactory 
bulb.  We found that recombinant antibodies against FMRP and FXR2P produced using 
the method described by Crosnier et al. (2010) could not recognize and bind their target 
epitopes (Figure 2.3b).  Thus, we were unable to produce functional antibodies through 
a fusion PCR-based approach and this pursuit was abandoned. 
Synbuild sequencing of VKL and VH of anti-FMRP N-terminus antibody  
Given the failings of the previously described method for the production of 
monoclonal antibodies, we turned to a more sequence directed approach.  If we could 
obtain the exact sequence of the variable regions for both light and heavy chains, we 
could design specific primers and eliminate the need for a degenerate primer battery.  
Furthermore, it would be possible to design primers that would introduce corresponding 
restriction sites within the variable regions and the joining fragments so that the entire 
contig could be assembled through standard ligation procedure rather than fusion PCR.  
Thus, we turned to the SynBuild sequencing facility, which was able to generate high-
quality sequences of the light and heavy chain variable regions of the anti-FMRP N-
terminus antibody from the total RNA.  We quickly identified conserved primary 
structures between the acquired sequences and the published mouse anti-NCAM2 
sequences present in the unaltered pTT3 vector.  The light chain possessed a 
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conserved Lys-Leu-Glu-Ile-Lys sequence at the C-terminus.  The heavy chain 
possessed a conserved Val-Gln-Leu-Gln-Gln sequence at the N-terminus.  We were 
able to take advantage of these homologies when designing primers to remove the anti-
NCAM2 light and heavy variable regions and introduce the anti-FMRP light and heavy 
variable regions.  Primers could possess these sequences from the parent construct, 
and then deviate to include sequences from the anti-FMRP variable regions. 
We then identified wobble positions flanking the conserved sequences that could 
be mutated to introduce restriction sites.  This approach required substitution of a 
cytosine for a thymine (C->T) 4 bases upstream of the conserved Gly-Thr-Lys-Leu-Glu-
Ile-Lys sequence in the light chain sequence.  The C->T substitution introduced a KpnI 
restriction site.  Priming within the anti-FMRP light chain variable sequence covered the 
last seven conserved residues (Gly-Thr-Lys-Leu-Glu-Ile-Lys).  The 3’ end of the variable 
light chain sequence was primed with primer 5’-GGCACTAAGCTGGAGATCAAA-3’ to 
introduce the KpnI site.  Underlined bases indicate necessary point mutations.  The 
joining fragment was then primed from the 5’ end with primer 5’- 
GGGACTAAGTTGGAAATAAAA-3’ to introduce the KpnI site.  In addition to introduction 
of the KpnI restriction site at the 3’ end of the variable light chain sequence, a NotI 
restriction site was required at the 5’ end for insertion into the pTT3 vector after ligation 
to the joining fragment.  Primer 5’-GCGGCCGCGATGTTGTGATGACC-3’ was designed 
to introduce the NotI site.   
The heavy chain variable sequence required several single base substitutions 
within a non-conserved sequence to introduce an AgeI restriction site.  Priming within 
this sequence covered the first three conserved residues (Leu-Gln-Gln).  An upstream 
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Glu residue was a Gln residue in the original pTT3 vector sequence.  Correction of this 
Gln to a Glu required priming of the joining fragment with primer 5’-GAGGTCCAACTG-
3’.  Downstream of the conserved Leu-Gln-Gln were non-conserved Ser and Val 
residues.  These residues were a Pro and Gly (respectively) in the joining fragment.  To 
convert the Pro residue to a Ser, primers 5’-GAGGTCCAACTGCAGCAGTCAGGA-3’ 
and 5’- GAGGTCCAACTGCAGCAGTCTGGA-3’ were designed.  To convert the Gly to 
a Val we used primer 5’-GAGGTCCAACTGCAGCAGTCTGGACCTGTC-3’.  These 
consecutive single base mutations prepared the joining fragment with the correct 
sequence of residues present within the variable heavy chain region of the anti-FMRP 
N-terminal antibody.  The AgeI restriction site was then added at the 3’ end of the 
joining fragment with primer 5’-GAGGTCCAACTGCAGCAGTCTGGACCGGTC-3’.  The 
AgeI restriction site could be introduced to the 5’ end of the heavy chain variable 
sequence through use of the same primer.  In addition to the introduction of the AgeI 
restriction site at the 5’ end of the variable sequence, an AscI site was required at the 3’ 
end for re-insertion into the pTT3 vector.  Primer 5’-
GGCGCGCCCTCACAGTCTCCTCA-3’ was designed to introduce the AscI site.   
Digestion of the anti-FMRP light and heavy chains with their respective restriction 
enzymes in  tandem with digestion of the joining fragment would allow for ligation of the 
complete contig given in Figure 1.2 without the need for fusion PCR.  Refer to Figures 







In summation, we were not able to produce functionally recombinant antibodies 
through a fusion PCR approach.  As a means of recourse, we directly sequenced the 
variable and light chain regions of the anti-FMRP antibody and developed a new 
strategy for inserting these sequences into the parent pTT3 vector.  The focus remained 
upon the production of anti-FMRP antibody.  The SynBuild sequencing results for the 
anti-FMRP variable regions (both chains) allowed for the design of primers that would 
allow for restriction cloning into the pTT3 vector.  This method of recombinant antibody 
production is not dissimilar from that used by Dodev et al. (2014), however this group 
did not make use of a joining fragment, presumably as the regions included in the 
joining fragment (see Figure 1.2) were included in their primer design. 
Nonetheless, the proposed method of restriction cloning may serve as a module 
for the swapping of antibody variable regions.  The product in each case would be a 
functional antibody corresponding to an IgG1.  This method would allow for multiple 
staining on western blots and in immunofluorescence, as any two antibodies that share 
an IgG sub-class (such as IgG2a or IgG2b) could be swapped to an IgG1.  We believe 





































Figure 2.1 Representative gel 
image of variable light and heavy 
chain PCR product amplified by 
degenerate forward primers.  PCR 
product was determined to be 
roughly 400 bp in size for both the 
VKL and VH. 
Figure 2.2 Representative PCR 
product from fusion of the VLK and 
VH to the joining fragment.  The 
major band running between 2.0 































Figure 2.3a Western blot of anti-
FMRP N-terminus antibody and 
anti-FXR2P antibody from 
HEK293T supernatant.  Light and 
heavy chain was recognized by 
donkey anti-mouse IgG secondary 
antibody in both cases.  Light and 
heavy chain from control antibody 


















































































































































































Figure 2.3b Western blot of tissue from mouse olfactory bulb.  Neither anti-FMRP 
experimental antibody (left) nor anti-FXR2P experimental antibody (right) recognized their 
target proteins in any tissue.  Upper bands with mass between 150 kDa and 100 kDa 
correspond to N-cadherin. 


































1.   5’-GAGGTCCAACTG-3’ 
Preparation of joining fragment 
2.   5’-GAGGTCCAACTGCAGCAG 
TCAGGA-3’ 
Figure 2.4a The 3’ end of the kappa light chain variable region from the 
pTT3 vector is given in red.  The 5’ beginning of the heavy chain variable 
region from the pTT3 vector is given in green.  The intervening joining 
fragment sequence is given in black.  Primers needed to introduce the 
proper mutations for restriction cloning (see text) are shown above and 
below the pTT3 sequence and include underlined bases as the sites of 
mutation.  A step process was used to prepare the 3’ end of the joining 
fragment to contain the proper sequence of residues present within the 
variable heavy chain sequence of the anti-FMRP N-terminus antibody.  Step 
4. Introduced the AgeI restriction site.  The 5’ primer that introduced the 
KpnI restriction site (shown above the red sequence) may be used as the 
forward primer in each step of preparing the 3’ end of the joining fragment 
sequence. 
3.   5’-GAGGTCCAACTGCAGCAG 
TCTGGACCTGTC-3’ 













5’-GAGGTCCAGCTGCAACAGTCTGGACCTGTG-[REMAINDER OF VARIABLE 



















Preparation of variable light chain and variable heavy chain 







Figure 2.4b The 5’ beginning of the kappa light and heavy chain variable regions 
from SynBuild sequencing are given in red.  The 3’ end of the kappa light and 
heavy chain variable regions from SynBuild sequencing are given in green.  
Corresponding primers to introduce the proper mutations for restriction cloning 
(see text) are shown below the original sequence and include underlined bases 
as the sites of mutation.  Primers shown above the original sequence include the 






























Compilation of primers and their functions 




Correction of a Glu to a Gln 
in joining fragment. 
5’-CAGTTGGACCTC-3’ 
 
5’-GAGGTCCAACTGCAGCAGTCAGGA-3’ Correction of a Pro to a Ser 




Correction of a Gly to a Val in 
joining fragment. 






























Introduction of AscI site in 
heavy chain. 5’-TGAGGAGACTGTGAG 
GGCGCGCC-3’ 
 
Figure 2.4c Required primers, their functions, and 
reverse compliments (in the case of reverse primers, 
see Figures 2.4a andb.) 
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Chapter III:  FMRP Isoforms within the Mouse Olfactory System 
Abstract 
The exact function of FMRP within mRNP particles remains the subject of 
hypotheses.  It has been proposed in this work that FMRP does not function alone, 
despite its ability to directly bind the ribosome (Chen et al., 2014).  Rather, FMRP likely 
associates with other proteins in a co-regulatory complex.  The nature of these co-
regulatory complexes may be dictated by the FMRP isoforms present within different 
regions of the neuron.  Here, we attempt to probe for specific FMRP isoforms within the 
mouse olfactory bulb; a region containing axons projecting from olfactory sensory 
neurons (OSNs) in the main olfactory epithelium (MOE).   
Introduction 
FMRP interacts with other proteins in the axon and in the dendrite.  Whether or 
not this defines a structural mechanism by which FMRP recognizes its target mRNAs 
remains to be determined.  The function of FMRP is of particular interest as the protein 
has only been shown to be spatially associated with homologues FXR1P and FXR2P in 
the FXG (Christie et al., 2009).  Is a spatial association sufficient to assume a physical 
association?  Are physical associations only transient and do not serve co-regulatory 
functions?  What other proteins are present within the FXG and how do they affect the 
ability of FMRP to bind mRNAs?  Given the size of mRNAs, it is likely that FMRP 
regulates translation in complex with other proteins.  These complexes are specific to 
those FXGs that include FMRP.  Furthermore, there exist multiple isoforms of FMRP.  
Certain isoforms possess a truncated RGG box or lack the RGG box entirely (Brackett 
et al., 2013), Dolzhanskaya et al., 2006a; Dolzhanskaya et al., 2006b).  In either case, 
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these isoforms cannot interact with other proteins or mRNAs in the same sense as full-
length FMRP (Dolzhanskaya et al., 2006b).  It may be the case that certain FMRP 
isoforms exhibit particular localizations in vivo, such that only particular co-regulatory 
complexes may form depending upon the region of the neuron (soma, dendrite, or 
axon).  Here, we are interested in FMRP isoforms present within the axon.  If we can 
elucidate specific FMRP isoforms unique to axons, we may begin to determine how 
these isoforms participate in the FXG, specifically with regard to FMRP interacting 
proteins (the co-regulatory complex) and mRNAs.  To address this question we used a 
genetic mouse model in which FMRP expression is normally silenced except in the 
presence of Cre recombinase (Wang, 2009).  By crossing these FMRP conditionally 
expressing (cON) mice with other mice that express Cre specifically in olfactory sensory 
neurons (OSNs), we could examine isoform-specific localization of FMRP within OSN 
axons.  As a control for Cre-induced FMRP expression, we collected tissues from 
mouse frontal cortex.  The frontal cortex would not possess Cre expression, and thus 
FMRP expression should be absence in tissues from FMRP Cre/cON crossed mice 
(Cre-cON). 
It is possible to divide the olfactory system into regions enriched for different 
structures of the OSN.  Specifically, the olfactory bulb (OB) is enriched in OSN axons 
projecting from cell bodies in the main olfactory epithelium (MOE).  The physiological 
division of the MOE and OB allows for the separation of OSN axons from the rest of the 
neuron (Mombaerts, 2006).  Examination of FMRP expression within the axon is of 
interest as the pre-synaptic understanding of mRNA translational regulation is not well 
understood.   
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FMRP has been shown to associate in FXGs with its homologues FXR1P and 
FXR2P in the axons of OSNs (Christie et al, 2009).  Through detection of components 
of mRNP particles in OSN axons, it would be possible to determine if FMRP regulates 
translation within these particles as a member of a co-regulatory complex.  We sought 
to first prove that there exist unique FMRP isoforms present within the axons of the 
OSN through a western blotting.  An FMRP blotting profile specific to the OB of 
conditionally expressing mice (see Figure 3.2) would provide evidence of axonal FMRP 
spliceforms.   
Materials and Methods 
Animal tissues  
MOE, OB, and frontal cortex were removed from P30 mice corresponding to wild-
type, conditional FMR1 expressing, non-conditional FMR1 expressing, and FMR1 
knock-out genotypes.  Tissues were flash frozen, and kept at -80°C.  Tissues were 
homogenized in a urea buffer (9 M urea, 4% CHAPS, 0.5% IPG, 50 mM DTT) with a 
tabletop homogenizer at 1 second pulses with a duty cycle of 4.  Total protein was 
quantified through BCA assay. 
Western blotting 
Volumes corresponding to 30 ug total protein from each tissue and genotype 
were resolved in an 8% SDS-PAGE gel.  As a control for dimerization due to high 
protein concentration, experiments were repeated with 7.5 ug total protein from each 
tissue and genotype.  Membrane-associated protein was bound by anti-bodies specific 
for the N-terminus (mouse IgG), C-terminus (rabbit IgG), and exon 12 (rabbit IgG) of 
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FMRP.  Primary antibodies were bound by fluorescing secondary antibodies specific for 
either mouse or rabbit IgG.   
Results 
Background expression in FMR1 cON tissue was excessively high in olfactory 
bulb tissue (Figure 3.2).  This remained true for each FMR1 cON animal used in this 
study.  We did not expect such high FMRP background expression within our cON 
tissues (see Figure 3.1).  Furthermore, the FMRP banding profile on the western blots 
for OB from cON tissue was identical to the FMRP banding profile from OB taken from 
Cre-cON tissue.  A difference in banding profile would indicate the presence (or 
absence) of an isoform of a particular mass within OSN axons relative to OSN cell soma 
and dendrites.  As there was no difference amongst the FMRP banding profile across 
tissues and genotypes, it was not possible to differentiate an OB (axon) specific isoform 
(or isoforms) in Cre-cON tissue from an MOE (cell soma, dendrite) specific isoform (or 
isoforms) in Cre-cON tissue.  The model was further invalidated by FMRP expression in 
frontal cortex from cON and Cre-cON mice.  The frontal cortex should not have been 
expressing Cre in either case, and such high FMRP expression in these tissues is 
attributable to off-target Cre-independent expression of FMR1 (Mientjes et al., 2006).  In 
summary, the model was complicated by 1) a lack of a unique FMRP isoform band in 
Cre-cON OB tissue and 2) activation of FMR1 in cON tissues independent of Cre 







The question was whether or not we could detect FMRP isoforms specific to the 
olfactory bulb of cre-cON mice.  These isoforms would be representative of FMRP 
isoforms that localize to the axons.  Characterization of these isoforms would allow for 
more robust probing of the components of the FXG, particularly those proteins that 
physically interact with FMRP.  However, the model proved insufficient at answering this 

































Figure 3.1 Expected FMR1 expression profiles in P30 mice.  Green triangles 
indicate FMR1 expression in the designated tissue, while grey triangles indicate no 
FMR1 expression in the designated tissue.  The genotypes shown represent the 






























Figure 3.2 Western blot of each tissue type labeled with anti-FMRP N-
terminal antibody.  Genotypes were loaded in the order indicated on the blot 
for each tissue type.  The FMRP mass range fell between 75 kDa and 50 kDa.   
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Chapter IV: Future Directions 
We have yet to test our method for the production of recombinant anti-FMRP 
antibody. Should this method prove successful, it shall be harnessed to produce other 
recombinant antibodies of interest.  The fusion PCR method of recombinant antibody 
production was unfortunately ill suited for our small-scale application.  While we were 
able to produce variable light and heavy chain PCR product of the appropriate length 
according to Crosnier et al. (2010), and such PCR product could be fused to the joining 
fragment to produce a complete sequence of the expected size, no functional antibody 
resulted from these endeavors.  Furthermore, the degenerate primer battery provided in 
Crosnier et al. (2010) could not amplify cDNA reverse transcribed from hybridoma 
secreting anti-rRNA antibody.  A good deal of energy was used in optimizing variable 
region PCR and fusion PCR, but such efforts proved fruitless. 
The mouse model of axonal FMRP expression was defeated on several fronts.  
High expression in cON without cre treatment in the olfactory bulb was the primary 
concern; however, FMRP expression in the cortex in any genotype excepting the wild-
type indicated further shortcomings of the model.  FMR1 expression should have been 
silenced in the cortex for cON, cre-cON, and KO genotypes, yet strong expression was 
observed in both the cON and cre-cON genotypes.   
We have exported Cre mouse line to a collaborator who possesses FMR1CTAG 
mice in which FMRP is expressed in all cells but specifically tagged with GFP in cells 
that express Cre.  A cross of these two mouse lines would yield Cre-cON GFP-FMR1.  
This would allow for FMRP::GFP to be selectively expressed within the MOE, and 
FMRP::GFP to localize throughout OSNs.  FMRP that localizes to the axons could be 
selectively isolated through GFP-pull down after isolation of the olfactory bulb.  This 
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would provide another means of identifying FMRP isoforms specific to the OB.  These 
experiments are ongoing and the first mice from them have been generated. 
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